share_log

Ocugen To Participate In Fireside Chat At Cantor Global Healthcare Conference Sept. 28 at 8 a.m. EDT

Ocugen To Participate In Fireside Chat At Cantor Global Healthcare Conference Sept. 28 at 8 a.m. EDT

Ocugen将参加9月9日Cantor全球医疗会议的炉边聊天28日上午8点EDT
Benzinga Real-time News ·  2021/09/23 16:19

Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8 a.m. Eastern Time. Dr. Musunuri will discuss COVAXIN™, the investigational COVID-19 vaccine which the company is co-developing with Bharat Biotech for the U.S. and Canadian markets. He will also present information about Ocugen’s breakthrough modifier gene therapy platform, which has generated product candidates that are expected to enter Phase 1/2a clinical trials in ophthalmic disease states over the next 18 months.

专注于发现、开发和商业化治疗失明疾病的基因疗法和对抗新冠肺炎的疫苗的生物制药公司欧库根公司(纳斯达克市场代码：OCGN)今天宣布，其董事长、首席执行官兼联合创始人尚卡尔·穆苏努里博士将出席2021年9月28日(星期二)上午8点举行的2021年坎托虚拟全球医疗大会。东部时间。穆苏努里博士将讨论COVAXIN™，这是该公司与巴拉特生物技术公司在美国和加拿大市场共同开发的一种新冠肺炎研究疫苗。他还将介绍欧库根公司突破性的修饰剂基因治疗平台的信息，该平台已经产生了候选产品，预计将在未来18个月内进入眼科疾病状态的1/2a期临床试验。

The fireside chat can be viewed live at https://wsw.com/webcast/cantor12/ocgn/2072070 and will be available within Ocugen’s Investor Relations page found at https://ir.ocugen.com.

炉边谈话可在https://wsw.com/webcast/cantor12/ocgn/2072070网站上现场观看，并可在欧库根公司投资者关系页面上观看，网址为https://ir.ocugen.com.。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发